Story
FDA mandates warnings for rare eye condition on GLP‑1 drugs
The FDA has ordered Ozempic, Wegovy and other GLP‑1 drugs to carry warnings about NAION, a rare eye condition that can cause blindness. This is a new requirement beyond prior labeling.
2 items2 outlets
First item: 10 November 2026Last update: 10 November 2026, 21:18
How outlets tell it
BBC NewsBBC reports that the FDA has mandated the addition of NAION warnings for GLP‑1 drugs such as Ozempic and Wegovy.- The GuardianThe Guardian highlights that the FDA has issued a new mandatory warning on GLP‑1 drugs about a rare eye condition that can lead to blindness.
Comparison based on feed headlines and summaries, not full articles.